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The inability of adult cardiomyocytes to divide to a significant extent and regenerate the
myocardium after injury leads to permanent deficits in the number of functional cells, which
can contribute to the development and progression of heart failure. The transplantation of
skeletal myoblasts or stem cells or cardiomyocytes derived from them into the injured
myocardium is a novel and promising approach in the treatment of cardiac disease and the
restoration of myocardial function. In this article, skeletal myoblasts and embryonic and bone
marrow stem cells are discussed in the context of their potential therapeutic use in cardiac
failure. The state of the art in both laboratory and clinic is presented. We discuss current and
intrinsic limitations of cardiac cellular transplantation and suggest directions for future
research. (J Am Coll Cardiol 2003;41:711–7) © 2003 by the American College of
Cardiology Foundation
Chronic heart diseases, such as ischemic and hypertensive
heart pathologies, are characterized by irreversible loss of
cardiomyocytes. Although terminally differentiated cardio-
myocytes have been described as showing some evidence of
mitotic division in the heart (1), the generally accepted
concept in contemporary cardiology is that adult cardiomy-
ocytes lack the ability to regenerate the myocardium, be-
cause they proliferate only up to the time of birth (2). This
leads to permanent deficits in the number of viable cardio-
myocytes and causes the development and progression of
heart failure (HF).
Angiotensin-converting enzyme inhibitors and beta-
adrenergic blockers have improved patient survival but are
not a substitute for living, beating cells. Additionally, the
development of non-pharmacological therapies, which may
range from mechanical assistance devices to artificial hearts,
holds great promise. Nevertheless, mortality remains high,
and long-term outlooks for patients are still uncertain.
Moreover, the contribution of heart transplantation to
reducing mortality is limited because of a shortage of donor
organs, the complications of immunosuppression, and the
functional failure of the transplanted organs.
Cell transplantation for treating cardiac disease represents
a tremendous opportunity for developing new therapeutic
strategies. In this review, transplantation of skeletal myo-
blasts and embryonic and bone marrow stem cells is dis-
cussed in the light of its potential contribution to cardio-
myocyte replacement therapies for injured myocardium. We
discuss advantages and limitations of each particular cell
type and suggest directions for future research.
SKELETAL MYOBLASTS
In contrast to the heart, the skeletal muscle contains
precursor cells, referred to either as satellite cells, because of
their location, or myoblasts, because of their capacity for self
renewal and differentiation; upon muscle injury these cells
become activated (3). Because skeletal myoblasts retain the
ability to regenerate throughout life and are less sensitive to
ischemic injury than cardiac cells, the idea emerged to
introduce these cells into the heart to repair the injured
myocardium and enhance its function. The potential of
these skeletal cells to do cardiac work was confirmed by the
biochemical and physiologic plasticity of skeletal muscle
induced by electrical depolarization and cardiac engraftment
(4–6). Although successful xenogeneic and allogeneic myo-
blast transplantation has been reported (7,8), the potentially
autologous origin of skeletal myoblasts is unlikely to raise
any immunologic or ethical problems. The relative ease with
which these cells are recognized, cultured, and multiplied in
vitro are other properties that make them eligible for clinical
use.
Chiu et al. (9) performed myoblast transplantation stud-
ies in a cryoinjury model of myocardial infarction (MI) in
dogs. The muscle in the implant sites appeared to be
mimicking cardiac muscle, including the presence of inter-
calated discs. Murry et al. (10) engrafted neonatal skeletal
myoblasts in cryoinjured rat hearts. By three months,
however, although the engrafted cells had formed skeletal
muscle, they never expressed cardiac-specific markers, sug-
gesting that there was no cardiac differentiation. Taylor and
colleagues (4,5) obtained physiologic improvement by trans-
plantation of autologous skeletal myoblasts and dermal
fibroblasts in rabbit heart damaged by cryoinjury. In a study
of MI induced by coronary artery ligation in rats, Scorsin
and co-investigators (11,12) studied the effect of skeletal
myoblast transplantation. Although left ventricular function
improved, no gap junctions were detected on the mem-
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branes of the skeletal cells, indicating impaired electrical
coupling.
Skeletal myoblasts are already being applied clinically.
Menasche et al. (13) reported successful implantation of
autologous skeletal myoblasts in a 72-year-old HF (New
York Heart Association [NYHA] class III) patient. Before
treatment, the myocardial scar was characterized as nonre-
versibly akinetic with absence of viability. After myoblast
engraftment, the akinetic wall became contractile and met-
abolically active, and the ejection fraction increased, chang-
ing the patient’s clinical classification to NYHA class II
disease within five months of cell transplantation.
In discussions about the limitations of these studies, it is
important to note that the skeletal myoblast transplantation
in this patient was combined with coronary artery bypass
grafting. This immediately puts the functional improvement
of the heart in a different light, because the beneficial effects
of the bypass surgery may have greatly influenced the
improvement of the patient’s clinical situation. Although
some of the findings are promising, we do not yet know
anything about long-term cell survival and terminal differ-
entiation of myoblasts after transplantation, although a
long-term effect of myoblast transplantation on heart struc-
ture and function has recently been reported (14). Another
important issue is the possible arrhythmogenicity of the
transplanted skeletal myoblasts. Their apparent inability to
transdifferentiate into cardiomyocytes and to form cardiac-
like syncytia with neighboring cells may create a new
substrate for ventricular re-entrant arrhythmias because
proper functioning of transplanted cells requires coupling
with host cardiomyocytes to allow impulse propagation.
This could turn every HF patient treated with myoblast
transplantation into a candidate for an implantable cardiac
defibrillator. The study by Chiu et al. (9) does suggest
cardiomyogenic transdifferentiation of myoblasts, but be-
cause labeling of the transplanted myoblasts was almost
indistinguishable from background tissue, it was impossible
to distinguish transplanted cells from recipient tissue un-
equivocally. Skeletal myoblasts could function by forming
electromechanical junctions between cardiomyocytes and
skeletal myotubes as observed in vitro by Reinecke and his
colleagues (15). However, the transient coupling observed
between skeletal myotubes and cardiomyocytes probably
reflected gradual down-regulation of connexin 43, which is
expressed at high levels in myoblasts. The skeletal cells also
possibly could contract in reaction to external mechanical
stimuli. However, given the ease with which contractile
responses of skeletal cells to mechanical stimuli could be
measured, the lack of published data on this suggests that it
does not occur. Furthermore, engraftment of the skeletal
cells could possibly have influenced the ventricular remod-
eling process, decreasing fibrosis and increasing hypertrophy
of viable cardiomyocytes.
EMBRYONIC STEM CELLS
Embryonic stem (ES) cells are derived from the inner cell
mass of blastocyst-stage embryos, and in culture they retain
the potential for unlimited, undifferentiated proliferation.
They are also pluripotent, which means that they are
capable of giving rise to every somatic cell type of the adult
organism as well as the germ cells (16). Long-term prolif-
erative capacity makes them suitable, in principle, for
large-scale culture. Furthermore, because of their capacity to
differentiate into cardiomyocytes, human ES cells may
furnish the basis of an excellent system for studying human
cardiomyocyte physiology and may provide an unlimited
supply of cells for the repopulation of damaged myocar-
dium.
Mouse ES cells. In vitro studies on mouse ES cells have
provided much insight into differentiation steps that lead to
the development of cells of the mammalian heart (17). To
induce differentiation of mouse ES cells into cardiomyo-
cytes, the cells are cultivated in aggregates in suspension to
form “embryoid bodies.” Spontaneously contracting areas
appear in 80% to 100% of embryoid bodies within 10 days,
depending on the particular cell line used (Fig. 1) (18,19). A
fairly defined sequence of transcription factor expression
controls the cardiogenic process in vitro and in vivo (20).
Activation of these pathways ultimately leads to the devel-
opment of heart excitability, myofibrillogenesis, ion channel
expression and function, calcium handling, and receptors
(21–26). In Figure 2, the sarcomeric banding pattern of
mouse ES cell–derived myocytes stained with -actinin is
shown. As ES cells are capable of differentiating into a wide
variety of cell lineages (27), only a small fraction of cells will
become cardiomyocytes. For this reason, Klug and col-
leagues (28) genetically modified mouse ES cells to select
cardiomyocytes from mixed cell populations. Expression of
a fusion gene in ES cell–derived cardiomyocytes rendered
the cells resistant to neomyocin and facilitated the selection
with G418 after in vitro differentiation. Non-neomyocin
resistant cells were killed in the selection medium. Evidence
confirming that G418-selected cells were indeed cardiomy-
ocytes consisted in the expression of sarcomeric myosin
immunoreactivity in the absence of immunoreactivity for
nebulin, a marker expressed early in skeletal myoblast
differentiation but not in cardiac myoblasts. These cultured
and genetically selected cardiomyocytes formed stable intra-
cardiac grafts with a normal myocardial structure when
transplanted into the healthy ventricular wall of dystrophic
mice. The same and other investigators showed that en-
graftment of fetal cardiomyocytes leads to the formation of
intercalated discs and gap junctions (29,30). However,
Abbreviations and Acronyms
ES  embryonic stem
HF  heart failure
MI  myocardial infarction
NYHA  New York Heart Association
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human fetal cells are difficult to obtain, are limited in their
ability to divide in culture, and are very sensitive to ischemic
injury. Further ethical, political, and practical constraints
would always preclude their use in routine therapy.
Human ES cells. Recently, human ES cell lines have been
described (16,31). Human ES cells are characterized by
immortality, expression of specific transcription factors and
cell surface molecules, and the ability to form derivatives of
all germ layers in vitro and in vivo. Co-culture of one cell
line with visceral endoderm-like cells induces differentiation
of human ES cells into beating muscle (32). The pluripotent
stem cells express a wide variety of receptors for growth
factors (33). Two factors, transforming growth factor 1
and activin-A, are known to promote differentiation into
mesodermal derivatives such as muscle cells. Kehat and
co-authors (34) clearly showed that one human ES cell line
can differentiate into myocytes with properties of cardiomy-
ocytes, with a mononuclear and round or rod-shaped
morphology and myofibrillar bundles and intercalated discs.
Cardiomyocyte-specific genes and proteins were expressed.
A recent study has described conditions under which up to
70% of the human ES-cell derivatives are cardiomyocytes
(35).
Before clinical application of ES cells becomes feasible,
the following major issues need to be addressed: 1) The
allogeneic origin of these cells raises immunological prob-
lems, and immunosuppressive drugs could be required to
prevent rejection. 2) The efficiency and culture conditions
for cardiomyocyte differentiation require optimalization. 3)
Nothing is known about cell survival and differentiation
after long-term transplantation into ischemic tissue. 4) Stem
cells can form cell types other than cardiomyocytes, and
because of their immortal state, the potential for tumor
development needs to be monitored. 5) Human ES cell
biology and research evoke important moral and ethical
issues, and this triggers debate throughout the world. In a
growing number of countries, legislation is being imple-
Figure 1. (A) Mouse embryonic stem (ES) cells (white arrows) cultured on mouse embryonic fibroblasts (black arrows). (B) Mouse ES cells cultivated in
aggregates in suspension to form floating embryoid bodies. (C) Mouse ES cells differentiated into beating muscle (white arrow) on visceral endoderm (black
arrow).
Figure 2. A-actinin immunohistochemical staining, dilution 1:400. Sec-
ondary antibody: goat anti-mouse IgG, dilution 1:250.
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mented to ensure that research is properly regulated and
controlled.
BONE MARROW STEM CELLS
Recent attention has focused on bone marrow as a source of
stem cells for transplantation into the heart. These cells also
retain the capacity for unlimited, undifferentiated prolifer-
ation and are capable of developing into different types of
cells, including cardiomyocytes (36–41). Different chemi-
cals have been reported to induce differentiation of bone
marrow cells into myogenic cells (40,42). Bone marrow, by
contrast with ES cells, can be collected from adults and used
for transplantation without posing ethical questions or
creating problems of tissue matching and rejection.
Makino et al. (38,39) developed an adult bone marrow
stromal cell line. These cells turned into myocytes and
connected with adjoining cells two weeks after 5-azacytidine
treatment. The cells then started beating spontaneously and
formed myotube-like structures. The differentiated cells
showed a cardiomyocyte-like morphology and cardiomyocyte-
specific immunostaining. Moreover, these cells expressed
characteristic cardiomyocyte genes and had characteristic
action potentials for cardiomyogenic cells, although it is of
note that these measurements were carried out at room
temperature and that skeletal and cardiac myocytes exhibit
similar action potentials under this condition. Adult rat
bone marrow cells were also induced by 5-azacytidine to
differentiate into myogenic cells expressing troponin I and
myosin heavy chain and then were transplanted into cryoin-
jured myocardium of an isogenic host (43). Muscle-like cells
apparently formed in the scar tissue, decreased the trans-
mural scar, stained positively for troponin I, and induced
significant improvements in ventricular function. Wang et
al. (44) demonstrated that donor bone marrow stromal cells
differentiate into cardiomyocytes after being implanted in
healthy myocardium. These cells expressed sarcomeric my-
osin heavy chain and formed gap junctions with host tissue.
Orlic et al. (45) described sorting and selection of most
multipotent bone marrow cells prior to transplantation in
mice. Multipotent bone marrow cells were selected for
combined expression of particular cell surface markers.
Donor cells were isolated from transgenic mice expressing a
green fluorescent protein (46). This protein facilitated
identification of the donor cells that were injected into the
damaged myocardium of recipient mice shortly after block-
ing the coronary blood flow. Within nine days, cells with
characteristics of cardiomyocytes, smooth muscle cells, and
endothelial cells occupied the major part of the damaged
area. Cardiac function improved and various myocyte-
specific genes were expressed. No long-term analyses were
made, however. Jackson and colleagues (47) transplanted a
highly enriched stem cell population from adult mouse bone
marrow in the bone marrow of lethally irradiated mice after
induction of myocardial ischemia. Two weeks after the
coronary occlusion, transplanted cells had homed to the
myocardial scar where they had formed cardiac myofibers
and played a role in neovascularization. Cell homing is the
process of cell-to-matrix and cell-to-cell interactions medi-
ated by a variety of cell-adhesion molecules that leads to the
anchoring of circulating cells to specific sites in the recipient
tissue. Orlic et al. (48) mobilized bone marrow cells in
infarcted mice by subcutaneous injection of stem cell factor
and granulocyte-colony stimulating factor. A band of newly
formed myocardium characterized healing of the infarct, a
feature that was absent in non-treated mice. A study by
Kocher et al. (49) showed that angioblasts derived from
bone marrow stem cells are able to prevent cardiomyocyte
apoptosis, reduce remodeling, and improve cardiac function
after MI in rats.
Although the results of these experiments were first
regarded as spectacular, they recently have been openly
criticized. No details about the long-term postoperative
survival of the cells were given in any of the engraftment
studies. The absence of either a repeat or a long-term
follow-up transplantation study of the approach taken by
Orlic et al. (45) is of crucial importance. Importantly,
because the expression of skeletal cell markers has not been
rigorously examined or reported, the identity of bone-
marrow derived cardiomyocytes as true cardiomyocytes is
still ambiguous. This is emphasized by the expression of
skeletal myogenic lineage determining genes in the car-
diomyogenic cells in the study by Makino et al. (38).
Furthermore, it is difficult to obtain multipotent cells in
sufficient quantities, because no specific markers of the true
stem cell have been identified. Bone marrow contains only a
very small number of these cells, and they are difficult to
maintain and to generate in vitro, growing extremely slowly
(50). Induction of differentiation into cardiomyocytes is far
from efficient. Another issue of concern is the formation of
other tissue types instead of muscle cells. If undifferentiated
cells are used, transplantation into scarred tissue might
induce differentiation into fibroblasts instead of cardiomy-
ocytes, or tumors may develop.
DIRECTIONS FOR FUTURE RESEARCH
All transplantation studies require rigorous, independent
validation, and many basic questions, such as those that
follow, need to be addressed before skeletal myoblasts, ES
cells, or bone marrow stem cells find their way into routine
clinical practice. What will the life span of the cells be after
engraftment? How will these cells behave once trans-
planted? Can they also form cell types that may have
detrimental effects on cardiac function, such as fibroblasts or
tumor cells? How many cells do we need to transplant, and
what is the best way to deliver these cells into the damaged
myocardium? Do ES cells need immunosuppression to
survive? Do the transplanted cells couple with neighboring
cells and propagate impulses properly? Will they adversely
affect heartbeat by forming an arrhythmogenic substrate?
An important issue in this research is to mark the cells in a
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proper way. Current failure to label the donor cells ade-
quately and to follow them in vivo makes it very difficult to
distinguish them from background tissue and could lead to
misinterpretation of the data. Reliable labeling techniques
and long-term transplantation studies in animals must
provide the necessary insights into cell migration, homing,
proliferation, and differentiation. The factors that influence
these processes remain to be discovered; so far we have only
clues. Depending on the desired effect of transplantation
and on the underlying cause of disease, we have to trans-
plant the right cell type(s). Do we need to transplant
differentiated cardiomyocytes, or can we use undifferenti-
ated cells if the purpose is to strengthen myocardial function
after cell loss due to hypertensive heart disease? In the case
of ischemic cell loss, not only do muscle cells need to be
replaced but also vascularization has to be restored. Other
causes of HF, such as cardiomyopathy, require nothing
more than a replacement of non-functioning cells by healthy
functional tissue. The different cell types have to be com-
pared extensively to give insight into the correct choice of
donor cell. We emphasize that future research requires a
clonality assay in order to generate pure cell populations
with specific morphologies and functions. Furthermore, we
need to explore further the possible existence of a cardiac
stem or progenitor cell in the body, able to regenerate
myocardial tissue, as reported in a study (51). Ischemia and
apoptosis might be of major importance in death of grafted
cells, as already suggested (52). With available nuclear
imaging techniques, the role of programmed cell death of
transplanted cells could be further clarified (53–56). Block-
ing ischemic influences and preventing initiation of apopto-
tic pathways has already enhanced donor cell survival
(52,57,58). Developing such strategies to prevent ischemic
and programmed cell death could be of major importance in
making cell transplantation a feasible therapy for cardiac
disease. Pharmacologic and genetic anti-death strategies can
be distinguished (52,57–60). So far, most cell transplanta-
tions have been carried out at the stage of acute MI. The
question is whether donor cells also can be introduced into
the chronically infarcted area of the heart and whether these
areas provide an environment for cells to survive, integrate,
and communicate with the host tissue and differentiate into
functional cells.
The cellular approach for treating cardiac diseases will
bring forth new insights in cardiac development and disease
because advances in developmental biology, genetic engi-
neering, and cell transplantation go hand in hand. To
optimize the progress in this research area, input from and
close cooperation between basic scientists—such as devel-
opmental biologists and geneticists, cardiac surgeons, and
cardiologists with different sub-specialties including electro-
physiology, interventional cardiology, and HF—will be
required. Their research should focus on cardiac develop-
ment as well as cardiac pathologies.
CONCLUSIONS
In this review, we surveyed results reported in research on
cell therapy for cardiac repair. In a very short period of time,
substantial progress has been made. Skeletal myoblasts have
already been introduced in the clinic in an experimental
setting. Stem cells of various sources can be cultured
indefinitely and induced to differentiate into cardiomyo-
cytes. Transplantation of these cells in infarcted tissue has
demonstrated limited restoration of myocardial structure,
improvement of ventricular function, and prevention of
myocardial remodeling in animals. In Tables 1 and 2, we
summarize the current state of the art of cardiac “engineer-
ing,” the use of skeletal myoblasts and stem cells, and the
characteristics of cardiomyocytes derived from them, re-
spectively (61). However, we are just at the beginning since
routine clinical therapy will require considerable fundamen-
Table 2. Markers of Cardiomyocyte Differentiation from Human Skeletal Myoblasts,
Embryonic, and Bone Marrow Stem Cells
Characterization of
Cardiomyocytes Derived From ‹
Human Skeletal
Myoblasts
Human
Cells
Human Bone Marrow
Stem Cells
Cardiac specific gene expression — (33–34) —
Cardiac specific proteins — (34) —
Gap junctions — (34) —
Myofibrillogenesis — (34) —
Electrophysiological recording — (34) —
Numbers in parentheses ( ) are reference numbers.
Table 1. State of the Art on Human Skeletal Myoblasts, Embryonic, and Bone Marrow
Stem Cells
Established techniques
Human Skeletal
Myoblasts
Human
Cells
Human Bone Marrow
Stem Cells
Unlimited self renewal in culture (61) (16–31) (37)
Differentiation into cardiomyocytes — (33–34) (37)
Transplantation into myocardium (13) — (49)
Improvement of myocardial function (13) — (49)
Numbers in parentheses ( ) are reference numbers.
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tal research on the development of appropriate cardiac
substrates and on the structure, function, and pathology of
cellular transplants. A multidisciplinary approach will be
necessary to understand the development of primitive cells
from whatever source into a robust three-dimensional car-
diac structure, in vivo as well as in vitro. Future investiga-
tions must provide more insight into these processes and
could lead to engineering of tissue homologues for treat-
ment of cardiac disease. Whether cell transplantation will
become an option for treatment of heart disease is not yet
clear, as too many gaps in our knowledge still exist.
Nevertheless, the promise and prospects for research and
disease therapy remain.
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